A Phase I/II Study of Trametinib plus Erlotinib in Patients with Erlotinib-Resistant Lung Adenocarcinoma


Full Title

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib


Most non-small cell lung cancers (NSCLC) with EGFR mutations treated with EGFR inhibitors (such as erlotinib) eventually come back or continue to grow despite this treatment. Researchers want to find out if adding trametinib to erlotinib therapy might make treatment more effective.

Trametinib is a drug approved for treating metastatic melanoma which works by blocking proteins called MEK1 and MEK2. Its use in this study is considered investigational. Both erlotinib and trametinib are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic or recurrent lung adenocarcinoma that has an EGFR mutation and has become resistant to erlotinib.
  • At least 2 weeks must pass since the completion of prior chemotherapy and 3 weeks since any radiation therapy or major surgery and entry into the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Helena Yu at 646-888-4274.